Article
Target selective activation of a TNF prodrug by urokinase type plasminogen activator (uPA) mediated proteolytic processing at the cell surface
Search Medline for
Authors
Published: | March 20, 2006 |
---|
Outline
Text
We have previously developed TNF prodrugs comprised of a N-terminal scFv targeting, a TNF effector and a C-terminal TNFR1 derived inhibitor module linked to TNF via a MMP-2 motif containing peptide, allowing activation by MMP-2 expressing tumor cells. Because of the known heterogeneity of matrix-metalloprotease expression, we exploited TNF prodrug processing by other tumor and/or stroma associated proteases by introducing peptide linkers with multiple cleavage sites. TNF prodrugs comprised of either a uPA selective or a dual specific uPA-MMP2 linker were constructed which displayed efficient, targeting dependent and cleavage sequence specific activation by tumor cell expressed proteases. Selective pharmacologic inhibition of endogenous uPA and MMP-2 confirm independent prodrug processing by these two model proteases and indicate the functional superiority of a prodrug containing a multi-specific protease linker. Processing optimized TNF prodrugs should increase the proportion of active therapeutic within the targeted tissue and thus potentially enhance tumor response rate.